Refine by
Disease Pad Articles & Analysis
17 news found
Hemostemix Inc. (TSX-V: HEM; OTCQB: HMTXF; FSE: 2VF0), an autologous (patient’s own) stem cell therapy company offering VesCell™ (ACP-01) to individuals suffering from peripheral arterial disease, chronic limb threatening ischemia, angina, ischemic cardiomyopathy, non ischemic dilated cardiomyopathy, congestive heart failure, and total body ischemia, under Florida’s SB 1768, ...
“Previous trials evaluating NOACs vs VKAs for stroke prevention in non-valvular atrial fibrillation have excluded patients with advanced chronic kidney disease. Therefore, the clinical impact of NOACs versus VKAs in this patient population was unknown. ...
ByBayer AG
Alucent is currently developing its Natural Vascular Scaffolding (Alucent NVS) Vessel Restoration System with Photoactivated Linking for the treatment of peripheral artery disease (PAD) of the lower extremities. The company announced today it will also seek to adapt the technology for another use, the maturation and preservation of arteriovenous fistula (AVF) for ...
The Ministry of Health, Labor and Welfare in Japan has approved the use of the oral Factor Xa inhibitor rivaroxaban (Xarelto™) (2.5 mg twice daily, used in combination with aspirin 81-100 mg once daily) to treat patients with peripheral artery disease (PAD) after revascularization. The approval is based on data from the Phase III VOYAGER ...
ByBayer AG
(NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, announced today that long-term data from the Disrupt PAD III trial found that superior vessel preparation with IVL led to excellent long-term outcomes out to two years with preservation of future treatment options compared to ...
The therapy is designed to open vessels and maintain patency without the use of permanent implants for the treatment of peripheral artery disease (PAD) of the lower extremities. PAD, a painful and debilitating condition, affects more than 200 million people globally. ...
Xarelto is the only Factor Xa anticoagulant FDA approved for pediatric patients and offers a flexible weight-based dosing Xarelto is available in both oral tablet and liquid suspension formulations for use in appropriate children less than 18 years of age Convenient liquid formulation advances standard of care for children; alleviates administration challenges found with injectable ...
ByBayer AG
Alucent Biomedical, a privately held medical technology company founded to transform the way vascular disease is treated, today announced the close of a $35 million Series B financing round led by a large multinational strategic investor and joined by another new investor, Fresenius Medical Care Ventures. ...
The therapy is designed to open vessels and keep them open without the use of permanent implants in the treatment of peripheral artery disease (PAD) of the lower extremities, a painful and debilitating condition affecting over 200 million people worldwide. ...
” CLI is a serious form of peripheral artery disease (PAD), a condition that affects more than 200 million people worldwide and results in the narrowing of blood vessels and reduced blood flow to the lower limbs. Decreased tissue oxygen levels in the lower limbs of PAD patients can lead to disabled walking, or in more advanced cases, ...
The system is designed to monitor compromised tissue in conditions such as peripheral artery disease (PAD) and critical limb ischemia (CLI). Both conditions result from a narrowing of blood vessels and reduced blood flow to the lower limbs. ...
The therapy is designed to treat peripheral artery disease (PAD) of the lower extremities, a painful and debilitating condition affecting over 200 million people worldwide. ...
This effort will build on previous stem cell studies that have shown promising results as a potential therapeutic option for this debilitating and increasingly common vascular disease. Six patients were treated in the opening week in the open-label registry study. ...
The REVEAL trial is a single arm, prospective study to evaluate the safety and effectiveness of the Revolution™ Peripheral Atherectomy System in the treatment of infrainguinal lower extremity peripheral arterial occlusive disease. 121 patients were successfully enrolled in 17 U.S. sites. The company will file a regulatory submission to the U.S. Food and Drug Administration ...
The regenerative medicine company is focused on finding therapies to repair tissues damaged by reduced blood flow due to disease or injury. The worldwide, exclusive licenses include patent rights to core intellectual property developed by Dr. ...
The company will initially market the system for monitoring tissue oxygen in the treatment of peripheral artery disease (PAD). With an annual economic burden of more than $74 billion dollars in the United States alone, PAD affects 202 million people worldwide. PAD leads to narrowing of blood vessels and reduced oxygenated blood ...
The company’s BioMimics 3D technology is based on research by Professor Colin Caro into the link between blood flow mechanics and vascular disease. Innovations first invested in Veryan in 2004 and as at 31 January 2014, the company held a 44.3% stake, with a carrying value of £16.97m (on £9.83m invested by Innovations). ...